MORGAN STANLEY PLC/CALL/AMGEN/440/0.1/21.03.25 | Real-time Bid/Ask 12:23:39 2024-06-04 EDT | ||
| 0.41 EUR / 0.44 EUR | +6.25% |
|
| Current month | +5.26% | ||
| 1 month | -24.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 0.41 | +2.50% |
| 24-06-03 | 0.4 | +5.26% |
| 24-05-31 | 0.38 | +8.57% |
| 24-05-30 | 0.35 | 0.00% |
| 24-05-29 | 0.35 | -12.50% |
Delayed Quote Börse Stuttgart
Last update June 04, 2024 at 11:59 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | ME1AJA |
| ISIN | DE000ME1AJA8 |
| Date issued | 2023-09-28 |
| Strike | 440 $ |
| Maturity | 2025-03-21 (290 Days) |
| Parity | 10 : 1 |
| Emission price | 0.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.62 € |
|---|---|
| Lowest since issue | 0.177 € |
| Spread | 0.03 € |
| Spread % | 6.82% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
307.4
USD
Average target price
316.3
USD
Spread / Average Target
+2.88%
- Stock Market
- Warrants
- Warrant
